Design of heparin oligosaccharide based molecules for inhibition of Alzheimer amyloid beta (Aβ40) aggregation

Thomas J. Paul, Harvey Kelly, Joshua Zuchniarz, Tahir Ahmed, Rajeev Prabhakar

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

In this computational study, we have combined molecular docking and molecular dynamics (MD) simulation techniques to explore interactions of monomeric and aggregated forms of Alzheimer's amyloid beta (Aβ40) with seven chemically distinct heparin derived glycoaminoglycans (GAGs) referred to as ADC, SDC, DC, V1, V2, V3, and V4. The docking procedure proposed two major binding sites, i.e., one present at the top of the fibril (site A), and the other located in the hairpin region (site B). Due to its position, site B offers an interesting target to design molecules with anti-aggregation properties. Our results predicted that out of seven GAGs, only three of them (ADC, SDC, and DC) bind to site B. The identification of these molecules can advance our efforts to develop therapeutic interventions for this deadly disease.

Original languageEnglish (US)
Pages (from-to)1090-1098
Number of pages9
JournalCanadian Journal of Chemistry
Volume94
Issue number12
DOIs
StatePublished - Aug 5 2016

Keywords

  • Amyloid beta
  • Amyloid fibril
  • Glycoaminoglycans
  • Heparin disaccharide

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Design of heparin oligosaccharide based molecules for inhibition of Alzheimer amyloid beta (Aβ<sub>40</sub>) aggregation'. Together they form a unique fingerprint.

  • Cite this